Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation

Brit Long, MD a,⁎, Brandon M. Carius, DSc, MPAS, PA-C b, Summer Chavez, DO, MPH d, Stephen Y. Liang, MD, MPH Sc, William J. Brady, MD e, Alex Koyfman, MD f, Michael Gottlieb, MD g

a SAUSHEC, Emergency Medicine, Brooke Army Medical Center, Fort Sam Houston, TX, USA
b 121 Field Hospital, Camp Humphreys, US Army, Republic of Korea
c Division of Emergency Medicine and Infectious Diseases, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, MO 63110, United States
d Department of Emergency Medicine, MedStar Georgetown University Hospital, 3800 Reservoir Road, NW, Washington, DC 20007, United States
e Department of Emergency Medicine, University of Virginia School of Medicine, Charlottesville, VA, United States
f The University of Texas Southwestern Medical Center, Department of Emergency Medicine, 5323 Harry Hines Boulevard, Dallas, TX 75390, United States
g Department of Emergency Medicine, Rush University Medical Center, Chicago, IL, United States

Abstract

Article history:
Received 28 November 2021
Received in revised form 1 January 2022
Accepted 12 January 2022

Introduction: Coronavirus disease of 2019 (COVID-19) has resulted in millions of cases worldwide. As the pandemic has progressed, the understanding of this disease has evolved. Objectives: This first in a two-part series on COVID-19 updates provides a focused overview of the presentation and evaluation of COVID-19 for emergency clinicians. Discussion: COVID-19, caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and mortality worldwide. Several variants exist, including a variant of concern known as Delta (B.1.617.2 lineage) and the Omicron variant (B.1.1.529 lineage). The Delta variant is associated with higher infectivity and poor patient outcomes, and the Omicron variant has resulted in a significant increase in infections. While over 80% of patients experience mild symptoms, a significant proportion can be critically ill, including those who are older and those with comorbidities. Upper respiratory symptoms, fever, and changes in taste/smell remain the most common presenting symptoms. Extrapulmonary complications are numerous and may be severe, including the cardiovascular, neurologic, gastrointestinal, and dermatologic systems. Emergency department evaluation includes focused testing for COVID-19 and assessment of end-organ injury. Imaging may include chest radiography, computed tomography, or ultrasound. Several risk scores may assist in prognostication, including the 4C (Coronavirus Clinical Characterisation Consortium) score, quick COVID Severity Index (qCSI), NEWS2, and the PRIEST score, but these should only supplement and not replace clinical judgment. Conclusion: This review provides a focused update of the presentation and evaluation of COVID-19 for emergency clinicians.

1. Introduction

Coronavirus disease of 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global pandemic [1-4]. The initial outbreak in late 2019 consisted of 27 patients with pneumonia in Wuhan, Hubei Province, China [1,2]. The virus spread rapidly around the world and was initially declared a pandemic on March 11, 2020 [1-3]. Recent variants, including the Delta and Omicron variants, have resulted in significant increases in cases [4]. As of December 31, 2021, over 287 million cases have occurred worldwide, with over 5.4 million deaths [4]. In the United States, there have been over 54.5 million confirmed cases and over 825,000 deaths [4]. This pandemic has resulted in significant challenges worldwide, and our understanding of this disease continues to evolve. This paper is the first in a two-part narrative review that will provide a focused update on the presentation and evaluation of COVID-19 for emergency clinicians.

2. Methods

A literature review of PubMed and Google Scholar databases was performed for articles up to December 31, 2021, using the keywords ‘COVID’ OR ‘COVID-19’ OR ‘SARS-CoV-2’ OR ‘coronavirus’ for this
narrative review. The authors included retrospective and prospective studies, systematic reviews and meta-analyses, clinical guidelines, and other narrative reviews. Commentaries and letters were also included. The literature search was restricted to studies published or translated into English. Authors reviewed all relevant articles and decided which studies to include for the review by consensus, with focus on emergency medicine-relevant articles, including guidelines. A total of 194 resources were selected for inclusion in this review.

3. Discussion

3.1. Virology and variants

SARS-CoV-2 is an enveloped positive-stranded RNA virus, which binds to the angiotensin-converting enzyme 2 (ACE2) receptor and enters cells via the coronavirus spike proteins 1 and 2 [1,3,5]. These spike proteins possess multiple cleavage sites, which may increase the pathogenicity of the virus [1,3,5-7]. Gradual accumulation of small genetic changes in these viral spike proteins results in antigenic drift and different variants. There are three types of variant classifications, stratified as those of interest, those of concern, and those of high consequence [5-19] (Table 1). The current variants of greatest concern include the Delta (B.1.617.2 lineage) and the Omicron variant (B.1.1.529 lineage) [5-19].

Viral particles are present in respiratory droplets, aerosols, blood, ocular secretions, urine, and stool, but it is primarily spread through direct person-to-person respiratory transmission [16-18,20-26]. The virus is spread from the mouth and nose as droplets and smaller aerosolized particles, which may become airborne and travel past 6 ft. [17,18,20]. Of note, over 50% of viral transmission occurs in those with no symptoms, and viral shedding may occur 3 days before the onset of symptoms [20,27]. With symptom onset, viral load peaks [20,27]. While contaminated surfaces are not thought to be a significant cause of transmission, infection may still occur if a person touches their eyes, nose, or mouth with contaminated hands. The incubation period is typically 4 to 5 days, though it ranges from 1 to 14 days [13,28-30]. The initial estimate of the reproductive number, or R0, of the virus was 4.7–6.6 (the number of expected cases originating from a single infected individual) [29]. With early infection control and vaccines, this number decreased to approximately 1.5 [30]. The Delta variant is significantly more transmissible, with an estimated R0 ranging between 6 and 7 [13,28]. The Omicron variant is even more transmissible, approximately 3.2 times that compared to the Delta variant and has a 3-day doubling time [31,32]. Transmission after 7–10 days of symptoms is highly unlikely [28].

The Delta variant is associated with higher viral loads, up to 1000 times higher than other strains, with earlier and prolonged shedding [11,19,28]. It is also associated with higher rates of hospitalization and mortality [11,19,28]. One study found the Delta variant was associated with higher odds of oxygen requirement, need for intensive care unit (ICU) admission, or death (adjusted odds ratio [aOR] 4.90, 95% confidence interval CI 1.43–30.78) [19]; other studies have found approximately double the risk of hospitalization [33,34]. A study of over 40,000 patients infected with COVID-19 also found a higher risk of hospitalization associated with the Delta variant, with an adjusted hazard ratio of 2.26 (95% CI 1.32–3.89) [34]. Evidence suggests vaccinated patients with the Delta variant have similar nasopharyngeal viral loads compared to non-vaccinated patients, even though they demonstrate fewer or even no symptoms [11].

The most recent variant of concern, B.1.1.529, also known as Omicron, was identified in South Africa on November 9, 2021, and reported to the World Health Organization (WHO) on November 24, 2021 [14,15]. The WHO declared it a variant of concern on November 26, 2021 [14]. By November 28, 2021, the variant had been identified in South Africa, Belgium, Botswana, Hong Kong, Israel, Italy, Netherlands, and the United Kingdom. By December 25, 2021, the variant was present in over 90 countries and made up over 58% of all new infections in the United States [32]. The Omicron variant possesses over 50 mutations and has quickly become the predominant strain in many countries [14,15,32,35]. While prior infection with SARS-CoV-2 was thought to provide an estimated 80% reduction in infection with other strains, evidence suggests the Omicron variant is associated with increased ability to evade immunity from prior infection [32,36-40]. Fortunately, recent literature suggests vaccinated patients have strong protection against severe illness from the Omicron variant [41-43]. While two vaccine doses without a booster demonstrate less effectiveness in preventing infection with the Omicron variant compared with other strains, data suggest two doses still reduce the risk of severe disease [41-43].

Data are controversial whether the Omicron variant is associated with reduced disease severity [43-45]. Several reports announced a decrease in disease severity, with one finding a 29% reduction in hospitalization rate in those infected with the Omicron variant [43-45]. A report released on December 22, 2021, found a 20–25% reduced risk of any hospitalization and 40–45% reduced risk of midday hospitalization [45]. Further studies are underway evaluating vaccine efficacy and the risk of severe disease associated with the Omicron variant.

3.2. Disease severity

COVID-19 infection is generally divided into symptomatic and asymptomatic, with symptomatic cases further categorized as critical, severe, and non-severe [2,46] (Table 2). The majority of patients have mild disease (over 80%) [2,3,46-48-33]. Clinically asymptomatic
infection rates may approximate 33% of those testing positive for COVID-19 based on one meta-analysis, but this number varies [20,47,48]. However, literature suggests severe disease (defined as hypoxia or > 50% lung involvement) can occur in over 15% of patients and critical disease (consisting of respiratory failure, multiorgan injury, or shock) in up to 5%, though this depends on the patient population [1-3,26,48,49]. More recently a third category of pre-symptomatic proposes that as many as half of these persons who do not declare symptoms at the time of positive testing develop symptoms later [47,50,51].

Reported rates of hospitalization, mechanical ventilation, and mortality vary significantly due to several variables including patient age, healthcare and testing availability, and containment measures, among others. Initial studies suggested high rates of hospitalization and mortality, but with current therapies and vaccination, risks of hospitalization, mechanical ventilation, and mortality have declined [1,2,20,52-67]. Early in the pandemic, overall mortality rates for admitted patients reached 20%, but in those admitted to the ICU, mortality approximated 40% [1,2,20,52-67]. As the pandemic has progressed, ICU survival rates have improved from 58% to 80% [62]. Of those hospitalized with COVID-19, up to 35% require admission to an ICU [20,48,52]. More recent literature suggests the case fatality rate is under 2% in all patients with COVID-19, though this depends on age [20,48,57]. In those over age 60 years this rises to 6.4%, in those over age 80 years it is over 13%, and in those over age 90 years mortality is over 25% [57].

Several factors are associated with worse prognosis in patients with COVID-19. Risk factors for severe disease include age > 75 years, diabetes, cancer, history of transplant, hypertension, and prior cardiac or pulmonary disease [23,26,52-67]. Obesity is associated with increased mortality and need for intubation, independent of other factors including race, sex, and other comorbidities, especially in patients less than 65 years of age [68,69]. One study suggested mortality was four-fold higher in patients with a body mass index (BMI) > 45 [69]. Heart failure is associated with longer hospital length of stay, increased need for intubation and ventilation, and mortality [70]. Unfortunately, the Delta variant is also associated with worse outcomes, including need for hospitalization, ICU admission, and mortality [33,71]. Other poor prognostic factors include an initial oxygen saturation < 88%, lymphopenia, thrombocytopenia, acute kidney injury, elevated lactate dehydrogenase, C-reactive protein (CRP) > 200 mg/L, D-dimer >2500 ng/mL, elevated troponin, and ferritin >2500 ng/mL [23,26,52,63].

3.3. Clinical presentation

Approximately 98% of patients who develop symptoms will do so within 12 days of viral exposure [3,20]. Although symptomatic COVID-19 patients exhibit a variety of signs and symptoms, most present with fever, changes in taste and/or smell, myalgias, and respiratory tract symptoms such as cough [1-3,20,52-76]. However, there are no clinical features with high enough specificity to reliably differentiate COVID-19 from other infections for diagnosis [75]. Literature suggests that the most common symptoms include cough (60–80%), shortness of breath (53–80%), and change in taste or smell disturbance (64–80%) [72-76]. Fever can be present in approximately half of patients at the time of initial presentation depending on the study, but overall, literature suggests 20–99% of patients experience fever during the course of the disease [1,2,18,23,49,53,72]. Literature varies on the definition of fever, with temperature thresholds as low as 37.1°C [75,77,78].

Viral pneumonia, hypoxic respiratory failure, and acute respiratory distress syndrome (ARDS) may result from COVID-19, with hypoxic respiratory failure the most common reason for ICU admission [1-3,20,23,60,74,75]. Bacterial or fungal co-infections affect up to 8% of patients [79]. These are a major source of morbidity and mortality; in one study, half of those who died experienced a secondary infection [23,80,81]. Bacterial respiratory infections most commonly include Streptococcus pneumoniae, Klebsiella pneumoniae, and Haemophilus influenzae, though other infections such as pulmonary aspergillosis and mucormycosis may also occur [80-87]. Mucormycosis has primarily been documented in India, with diabetes and steroid treatment the most common risk factors [84-87]. Concurrent viral infections are also common, with one study finding 20.7% of patients with COVID-19 infected with at least one other virus [82].

3.4. Extrapulmonary presentations and complications

3.4.1. Cardiac

As the pandemic has progressed, a variety of extrapulmonary effects have been uncovered. Myocardial disease, manifested by dysrhythmias, acute coronary syndrome (ACS), heart failure, and myocarditis [22,88-90], occur in over 20% of patients admitted to the ICU with COVID-19 [22]. Dysrhythmias include AV blocks, bradycardia, and supraventricular and ventricular tachycardias [22,88-90]. Torsades de pointes may occur due to QT prolongation. The QT interval can be prolonged due to electrolyte changes (diarrhea, dehydration), systemic inflammation, and comorbidities (preexisting cardiac disease) [88,91,92]. ACS is likely associated with severe inflammation [88-96]. This may result in plaque rupture and ST elevation myocardial infarction [93-95]. Cardiomyopathy, heart failure, and myocarditis can also occur, with acute left heart failure occurring in 23% of patients [23,88,90,92]. Left heart failure is associated with increased mortality and was present in 52% of those who died in one study [23]. Right heart failure is more likely associated with lung injury and ARDS, as well as the hyperinflammatory state, thrombotic events, and viral damage [96,97]. Literature suggests right ventricular dilation occurs in 20–31% of cases [96,97]. Myocarditis is more likely in those with heart failure or shock who have no prior history of cardiac disease [88,90]. Myocarditis was the cause of death in 7% of patients and contributed to one third of deaths in one study [23]. However, cardiac involvement is likely more common than originally thought. One study of patients with mild to moderate COVID-19 who underwent cardiac magnetic resonance imaging found abnormal findings in 78%, most commonly cardiac inflammation [98], and a second study found 56% of patients had cardiac inflammation and edema [99]. Other studies suggest cardiac involvement is present even in patients with minimal or no symptoms [100].

3.4.2. Neurologic

Neurologic effects associated with the disease vary, ranging from mild illness to severe manifestations such as stroke. Up to 80% of patients experience neurologic symptoms during the course of the disease [101]. Mild symptoms such as headache and dizziness affect up to 40% of patients during acute illness, which may increase as the illness progresses [101-103]. Changes in smell and taste are common. This may be the first symptom in approximately one-third of patients [102,103]. Up to 80% of patients will experience a change in taste or smell during the course of illness, and almost half will have complete loss of taste or smell [72,75,103,104]. Literature suggests severe neurologic complications occur in a significant number of patients with COVID-19, including seizure, encephalopathy, and cerebral ischemia [105]. Mental status changes due to encephalopathy are more common in older patients with COVID-19 and associated with worse outcomes [101,105], with
delirium occurring in up to 55% of critically ill patients with COVID-19 [106]. Meningoencephalitis may occur due to direct central nervous system (CNS) invasion or systemic inflammation due to COVID-19. Immune-mediated complications such as Guillain–Barre Syndrome and myasthenia gravis have been reported [107]. Cerebral ischemia due to stroke may occur in up to 6% of critically ill patients with COVID-19 and can present as small or large vessel occlusion; however, the risk of cerebrovascular accident (CVA) is less than 1% in other populations with COVID-19 [108–110]. CVA most commonly occurs in the first several weeks after symptom development [108–110]. While rare, cerebral venous thrombosis has also been documented and is associated with high mortality rate in COVID-19 [111,112]. These patients can present with headache, seizure, focal neurologic deficit, or altered mental status. Acute disseminated encephalomyelitis and posterior reversible encephalopathy syndrome have also been reported. Finally, patients are at risk of psychiatric complications such as mood disorders, anxiety, insomnia, and psychotic disorders [103,113].

3.4.3. Gastrointestinal
Gastrointestinal (GI) symptoms are common, with up to one-third of patients with COVID-19 presenting first with GI symptoms [24,114,115]. Nausea and vomiting may be present in up to two-thirds of patients with COVID-19 [115]. Approximately 40% of patients with COVID-19 will have loss of appetite, and up to 50% will have diarrhea [24,115]. Abdominal pain is less common, occurring in less than 10% [24,115]. In critically ill patients, acute liver injury, cholecystitis, pancreatitis, ileus, pseudo-obstruction, and mesenteric ischemia may occur [116].

3.4.4. Dermatologic
Dermatologic manifestations of COVID-19 occur in 0.4–20% of cases but are often non-specific consisting of erythema or urticaria-like lesions on the trunk or, less frequently, the extremities [74,117–121]. Similarly, small case series and reports describe livedo reticularis, vesicular eruptions, maculopapular lesions, and areas of thickened erythema resembling chilblains [117–121]. New pernio-like lesions are also suggestive of COVID-19 [74,118].

3.4.5. Hematologic/thrombotic
Hematologic issues including thrombotic complications are common in critically ill patients with COVID-19. This risk is thought to be associated with systemic inflammation [122–132]. Initial studies suggested patients with COVID-19 were at a high risk of venous thromboembolic event (VTE), with rates of VTE reaching 31% in critically ill patients [122,124–126]. More recent studies have found that the overall risk of VTE, including pulmonary embolism (PE), in patients with COVID-19, no matter the severity of illness, is lower than initially suspected (<1%), though the risk remains higher than the general non-COVID-19 population [132]. A second international study found COVID-19 was not an independent risk factor for PE, with 15% in the pandemic era and 15% of patients in the prepandemic era experiencing PE [132]. Routine evaluation for PE in all COVID-19 patients is not recommended [132]. Evaluation for PE should be considered in patients with other risk factors for PE; those with hypoxia, tachycardia, or hypotension out of proportion to clinical evaluation; sudden decompensation; or those whose symptoms are not explained by chest radiograph.

3.5. ED evaluation

3.5.1. SARS-CoV-2 testing
Evaluation in the ED setting primarily focuses on identification of COVID-19 and assessment for severe illness and end-organ injury [1–3]. Identification of COVID-19 infection continues to rely heavily on nucleic acid amplification tests (NAAT) for SARS-CoV-2 in nasopharyngeal specimens, with reverse transcription polymerase chain reaction (RT-PCR) assays comprising common methods recommended by the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and Infectious Diseases Society of America (IDSA) [1–3,20,74,133–139]. Initial concerns for suboptimal sensitivities of RT-PCR as low as 70% have been attributed to oropharyngeal sampling and poor sampling technique, while accuracy has significantly improved with nasal vestibular and middle turbinate swabs or the use of saliva [133–140]. Sensitivity may approach 100% when there is 500–5000 viral RNA/mL [135]. However, timing of testing can have significant impact on RT-PCR test characteristics, with the highest sensitivity at 2–3 days after symptom onset and the lowest sensitivity immediately after exposure [20,138].

Although RT-PCR can be performed in a condensed timeline, the sheer volume of tests performed in major centers has prompted examination of shorter-turnaround point-of-care testing, such as rapid SARS-CoV-2 antigen (Ag) testing to detect viral proteins. This process utilizes a nasal turbinate swab with a simple qualitative indicator when reagent is applied, with results available in approximately 15 min compared to the 60–120 min required for NAAT [140–145]. Despite generally high specificity, SARS-CoV-2 Ag testing demonstrates highly variable sensitivity (31–93%), likely due to varying viral loads, and it has less sensitivity at lower viral loads [20,133,137–140–145]. Most SARS-CoV-2 Ag tests demonstrate higher sensitivities with a lower cycle threshold (Ct), which describes the number of PCR cycles required to detect the virus [141–144]. SARS-CoV-2 Ag tests demonstrate higher sensitivities for those with a PCR Ct of ≤25, compared to those with higher Ct values [133,137,140–145]. Due to this variability, SARS-CoV-2 Ag testing can be considered for rapidly screening patients who appear highly symptomatic with suspected or confirmed exposure. Current society guidelines recommend that SARS-CoV-2 Ag testing be employed in isolation only when NAAT is not available, or as screening for patients in conjunction with NAAT for definitive diagnosis (Fig. 1) [20,140,143]. Limited evaluation of SARS-CoV-2 Ag tests against Omicron variant infections do not demonstrate a significant decrease in overall sensitivity for symptomatic individuals [146,147].

3.5.2. Other laboratory testing
Patients with normal vital signs who appear well do not require laboratory assessment other than SARS-CoV-2 testing. However, additional laboratory testing can assist with risk stratification in determining the need for admission [1–3,20]. A complete blood count (CBC) can provide several markers of interest. For example, the CBC may reveal lymphopenia (absolute lymphocyte count <1.0 × 10^9/L), which can be found in up to half of patients overall and 83% of hospitalized patients, portending an increased risk for the combined outcome of severe disease course and mortality compared to those with normal levels (76% vs. 26%, p < 0.001) [20,38,148–155]. Lymphopenia tends to worsen with the severity of COVID-19 symptoms and is associated with an increased risk for respiratory failure (odds ratio [OR] 2.69, p < 0.001) [152–155]. Total leukocyte counts are variable but generally remain within a normal range of 4–10 × 10^9/L, though median values for more severe patients are more commonly below this lower limit at 3.7–3.9 × 10^9/L [18,20,151,155]. Mild thrombocytopenia (platelet count <150 × 10^9/L) is seen in 12–33% of patients overall, with a higher proportion found in those with more severe illness (57.7% vs. 31.6%) [18,20,149,151,153,155].

Chemistry and liver function testing can be obtained to evaluate for organ injury and other complications in COVID-19 patients. Serum creatinine has been found to be elevated in less than 10% of patients, although one study found elevated creatinine in 28.8% of patients [18,154–159]. Common electrolyte derangements found in COVID-19 include hypernatremia (20.4–50%) and hypokalemia (15.1–62%), with most exhibiting mild depletion (Na 130–135 mmol/L, K 3.0–3.5 mmol/L) [53,156–159]. Lower sodium levels have been associated with more severe illness (139 mmol/L vs. 136 mmol/L, p = 0.0001) [53,157,160]. Those with severe hypokalemia (<3 mmol/L) are also more likely to have severe COVID-19 (p < 0.001) [157,158]. Hyperglycemia is found in approximately half of patients, and in patients with diabetes, a venous blood gas panel should be considered to evaluate for COVID-19.
triggered diabetic ketoacidosis [153,161,162]. Lactate dehydrogenase (LDH) is elevated (>250 U/L) in 27–92% of COVID-19 patients [18,20,149,151-155].

Liver function tests demonstrate statistically significant elevations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in 10–28% and 9–36% of patients overall, respectively; however, at this time the clinical significance of this is not well established [20,148,153,155]. Scattered case reports suggest COVID-19 can present as acute hepatitis, while small studies show elevated AST and ALT in COVID-19 with preexisting hepatitis B infection [163,164]. However, there is no clear correlation at this time.

As in most inflammatory processes, inflammatory markers including CRP and erythrocyte sedimentation rate (ESR) tend to be elevated in COVID-19. This includes significant CRP elevation (≥10 mg/L) in 46–99% COVID-19 patients [18,20,149,151-155]. ESR is elevated (> 15 mm/h) in 24–96% of patients, albeit with less supporting studies relative to CRP [53,149,153,155]. CRP ≥10 mg/L demonstrates increased risk of respiratory failure (OR 5.91) and thrombotic events (OR 2.7) in COVID-19 patients, while ESR > 40 mm/h shows similar association with thrombosis (OR 2.64) in isolated studies [127,151,152].

Potential thrombotic complications may prompt evaluation for fibrinogen and coagulation studies, with serum D-dimer often elevated. While studies vary on D-dimer levels to define elevation, 46% of COVID-19 patients demonstrate levels >0.5 mg/L and 36% have levels >1.5 mg/L [20,127,149,153,165]. The predictive ability of elevated D-dimer for thrombotic events in these patients increases proportionally to the elevation, with increasing risk from 1 to 2.5 mg/L (OR 1.75) to >2.5 mg/L (OR 4.40), 5–10 mg/L (OR 5.55) and ≥10 mg/L (OR 7.09) [127-130]. The degree of D-dimer elevation is also associated with severity of illness, with higher levels associated with more severe disease [155]. Less often, prolonged prothrombin (PT) and activated partial thromboplastin (aPTT) times are found in approximately 5–11% and 6–26% of patients, respectively, without significant correlation between abnormal levels and illness severity or bleeding complications [20,53,119,120,153,155].

3.5.3. Imaging

Chest radiography is generally employed for initial evaluation of COVID-19 patients with respiratory symptoms, although studies reveal significant variation in the frequency of their findings [1-3,18,166-172]. A normal chest X-ray (CXR) may be found in a significant proportion of patients with COVID-19 (5.6–53.6%), with 10.9% later progressing to abnormal findings on subsequent plain films [18,166-172]. Scattered case reports suggest COVID-19 can present as acute hepatitis, while small studies show elevated AST and ALT in COVID-19 with preexisting hepatitis B infection [163,164]. However, there is no clear correlation at this time.
consists of consolidation (days 9–13), and stage 4 is gradual resolution (days ≥14) [174].

Lung ultrasound (LUS) is another tool in the evaluation of COVID-19 patients. A prospective cohort study found that LUS possessed a sensitivity of 94.4% for diagnosis and was able to identify false-negative cases on PCR [175]. A meta-analysis reported moderately high sensitivity (86.4%) but low specificity (54.6%) [172]. LUS findings in patients with mid-to-moderate respiratory symptoms include abnormal pleural thickening and sliding, B-lines, skip lesions, and small areas of patchy consolidation, with the posterior lung fields most commonly affected (Fig. 4) [175-183]. B-line progression with enhanced consolidation suggests increasing disease severity and should raise concern for a potential need for enhanced respiratory support [176,177,179].

3.6. Risk scores

Over 20 prognostic scoring systems have been created for COVID-19. This review will not discuss all of these scores. Many of these scoring tools are a combination of clinical, laboratory, and imaging findings [184-194], and unfortunately, many of these have proven unreliable in the clinical setting. These scores are primarily derived from homogenous, small populations of patients, and many lack extensive validation or are too complex for clinical use [184,185]. However, several demonstrate utility when used appropriately. When utilized, these scores should supplement clinical decision making, but they cannot replace clinical judgment [194].

One of the most robust and validated scores to predict mortality in patients with COVID-19 is the 4C (Coronavirus Clinical Characterisation Consortium) score. The 4C score has been validated in several settings in over 57,000 patients and considers age, sex, comorbidities, respiratory rate, oxygen saturation on room air, Glasgow Coma Scale, blood urea nitrogen, and CRP (Table 3) [186,187]. The derivation receiver-operator characteristic (ROC) curve was 0.79, with 0.77 in the validation cohort (ROC 0.5 suggests no discrimination, 0.7–0.8 suggests an acceptable level of discrimination, and greater than 0.8 is considered excellent) [186,187].

The quick COVID Severity Index (qCSI) is an effective physiological risk score that can be used at the bedside. It was initially created to

---

1 Asymptomatic people who are fully vaccinated should follow CDC’s guidance on testing for people who are fully vaccinated. Asymptomatic people who have had a SARS-CoV-2 infection in the last 3 months should follow CDC’s guidance on testing for those within 90 days of their initial infection.

2 This antigen negative may need confirmatory testing if the person has a high likelihood of SARS-CoV-2 infection (e.g., the person has had close contact with or suspected exposure to a person with COVID-19 within the last 14 days and the person is not fully vaccinated and has not had a SARS-CoV-2 infection in the last 3 months).

3 This antigen positive may need confirmatory testing if the person has a low likelihood of SARS-CoV-2 infection (e.g., the person has had no known or suspected exposure to a person with COVID-19 within the last 14 days or is fully vaccinated or has had a SARS-CoV-2 infection in the last 3 months).

4 This antigen negative may not need confirmatory testing if the person has a low likelihood of SARS-CoV-2 infection (see above).

5 This antigen positive may need confirmatory testing if the person has a low likelihood of SARS-CoV-2 infection (see above).

6 For those who are traveling or have recently traveled, refer to CDC’s guidance for domestic and international travel during the COVID-19 pandemic.

7 People who are fully vaccinated and those who have had a SARS-CoV-2 infection in the last 3 months do not need to quarantine. Others should consider serial antigen testing if they have had contact with a person who has COVID-19 within the last 14 days.

---

Fig. 2. Chest x-ray with bilateral ground-glass opacities From: https://commons.wikimedia.org/wiki/File:COVID-19_Pneumonie_-_82m_Roe_Thorax_ap_-_001.jpg
determine risk of progressing to respiratory failure and critical illness within 24 h of hospital admission and is comprised of respiratory rate, pulse oximetry, and supplemental oxygen flow rate (Table 4) [188]. The initial ROC curve was 0.81, with other studies suggesting the score may be similar to the NEWS score and outperform other risk scores such as 4C and CURB-65 [188,189].

NEWS2 is another physiologic score comprised of respiratory rate, saturation, systolic blood pressure, pulse, consciousness, and temperature [190-192] (Table 5). This score demonstrates area under receiver operating characteristic (AUROC) curves of 0.78 for determining who will deteriorate over 24 h and for in-hospital mortality [192].

The PRIEST score, comprised of respiratory rate, oxygen saturation, heart rate, systolic blood pressure, temperature, alertness, inspired oxygen, sex, age, and performance status, reported a c-statistic of 0.80, with a score > 4 demonstrating a 98% sensitivity and 34% specificity to predict adverse events [193] (Table 6).

4. Conclusions

COVID-19 has resulted in millions of infections and deaths. The disease is primarily spread by respiratory droplets and aerosols. Several variants have arisen, including the Delta (B.1.617.2 lineage) and...
Table 4

| qCSI Variable | Points |
|---------------|--------|
| Respiratory rate in breaths per minute | |
| ≤22 | 0 |
| 23–28 | 1 |
| >28 | 2 |
| Peripheral oxygen saturation on room air | |
| ≤88% | 5 |
| 89–92% | 2 |
| >9% | 0 |
| O2 flow rate, L/min | |
| ≤2 | 0 |
| 3–4 | 4 |
| 5–6 | 5 |
| Score | Risk of critical illness at 24 h |
| 0–3 = Low risk | 4% |
| 4–6 = Low-intermediate risk | 30% |
| 7–9 = High-intermediate risk | 44% |
| 10–12 = High risk | 57% |

Table 5

| NEWS2 Variable | Points |
|----------------|--------|
| Respiratory rate in breaths per minute | |
| ≤8 | 3 |
| 9–11 | 1 |
| 12–20 | 0 |
| 21–24 | 2 |
| ≥25 | 3 |
| SpO2 (on room air or supplemental) | |
| ≤91% | 3 |
| 92–93% | 2 |
| 94–95% | 1 |
| ≤96% | 0 |
| SpO2 (if patient has hypercapnic respiratory failure) | |
| ≤83% | 3 |
| 84–85% | 2 |
| 86–87% | 1 |
| 88–92%, ≥93% on room air | 0 |
| 93–94% on supplemental oxygen | 1 |
| 95–96% on supplemental oxygen | 2 |
| ≤97% on supplemental oxygen | 3 |
| Oxygen Supplemental oxygen | 2 |
| Room air | 0 |
| Temperature | |
| ≤35.0 °C (95 °F) | 3 |
| 35.1–36.0 °C (95.1–96.8 °F) | 1 |
| 36.1–38.0 °C (96.9–100.4 °F) | 0 |
| 38.1–39.0 °C (100.5–102.2 °F) | 1 |
| ≥39.1 °C (102.3 °F) | 2 |
| Systolic BP, mm Hg | |
| ≤90 | 3 |
| 91–100 | 2 |
| 101–110 | 1 |
| 111–120 | 0 |
| ≥121 | 3 |
| Pulse, beats per minute | |
| ≤40 | 3 |
| 41–50 | 1 |
| 51–90 | 0 |
| 91–110 | 1 |
| 111–130 | 2 |
| ≥131 | 3 |
| Consciousness | |
| Alert | 0 |
| New onset confusion, responds to voice or pain, or unresponsive | 3 |
| Score | |
| 0–4 = Low risk | |
| 5–6 = Medium risk | |
| 7 = High risk | |

### Omicron (B.1.1.529 lineage) variants.
Most patients experience a mild infection with upper respiratory symptoms, fever, and change in taste/smell, but some may develop severe infection with respiratory failure and end organ injury. Aside from the respiratory system, SARS-CoV-2 can affect the cardiovascular, neurologic, gastrointestinal, and dermatologic systems. Evaluation includes identification of COVID-19 and assessment for end organ injury. Several risk scores may assist in prognostication.

### CRediT authorship contribution statement

**Brit Long:** Writing – review & editing, Writing – original draft, Visualization, Conceptualization, **Brandon M. Carius:** Writing – review & editing, Writing – original draft, **Stephen Y. Liang:** Writing – review & editing, Writing – original draft, Supervision, **Summer Chavez:** Writing – review & editing, Conceptualization, **William J. Brady:** Writing – review & editing, Conceptualization, **Alex Koyfman:** Writing – review & editing, Conceptualization, **Michael Gottlieb:** Writing – review & editing, Writing – original draft, Supervision, Conceptualization.
Declaration of Competing Interest

None

Acknowledgements

All authors conceived the idea for this manuscript and contributed substantially to the writing and editing of the review. This manuscript did not utilize any grants, and it has not been presented in abstract form. This clinical review has not been published, it is not under consideration for publication elsewhere, its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. This review does not reflect the views or opinions of the U.S. government, Department of Defense, U.S. Army, U.S. Air Force, or SAUSHEC EM Residency Program.

References

[1] World Health Organization. WHO coronavirus 2019 (COVID-19) pandemic. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019; 2021.

[2] Centers for Disease Control and Prevention. COVID-19. Available at: https://www.cdc.gov/coronavirus/2019-ncov/index.html. Accessed August 21, 2021.

[3] Chavez S, Long B, Kofyan A, Liang SY. Coronavirus disease (COVID-19): a primer for emergency physicians. Am J Emerg Med. 2021 Jun;44:220–9.

[4] Johns Hopkins University and Medicine. Coronavirus Resource Center. Available at: https://coronavirus.jhu.edu. Accessed August 21, 2021.

[5] Belouzard S, Miller JK, Licitra RN, Whitaker CR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012;4(6):1011–33.

[6] SARS-CoV-2 variant classifications and definitions. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html#consequence. Updated July 13, 2021. Accessed July 19, 2021.

[7] Centers for Disease Control and Prevention. What you need to know about variants. November 27, 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant.html. Accessed November 27, 2021.

[8] Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538). https://doi.org/10.1126/science.abc3055. eabc3055.

[9] Zimmer C. The New COVID Variant in the UK. The New York Times; 2021. Updated March 6. Accessed July 19, 2021.

[10] Hart R. Pfizer Shot Much Less Effective Against Delta. Israel Study Shows – Here’s what You Need To Know About Variants And Vaccines. Forbes; 2021. Published July 6. Accessed July 30, 2021.

[11] Dyer O. Covid-19: delta infections threaten herd immunity vaccine strategy. BMJ. 2021;374:n1933. Published 2021 Aug 2. https://doi.org/10.1136/bmj.n1933.

[12] Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) variant compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). The Lancet. 2021 Apr 17;397(10283):1470–6.

[13] Del Rio C, Malani PN. COVID-19: new insights on a rapidly changing epidemic. BMJ. 2020;370:969.

[14] World Health Organization. WHO coronavirus 2019 (COVID-19) pandemic. Available at: https://www.who.int/data/ briefing/situation-reports/coronavirus-covid-19; 2021.

[15] Centers for Disease Control and Prevention. COVID Data Tracker. Centers for Disease Control and Prevention. https://covid.cdc.gov/covid-data-tracker/#variant-proportions. Accessed December 27, 2021.

[16] Sheikh A, McMenamin J, Taylor B, Robertson C. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant [published online ahead of print, 2021 Jul 21]. Eur J Epidemiol. 2021. https://doi.org/10.1007/s10657-021-01122-0.

[17] Ong SWX, Chiew CJ, Ang LW, et al. Clinical and virological features of SARS-CoV-2 lineage B.1.617.2 in Singapore. Trans Microbiol. 2021;52(5):698–706. https://doi.org/10.1111/tmbi.13442.

[18] Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020 May 12;323(18):1843–4.
